Objectives: The aim of this study was to investigate whether sclerostin (SOST) regulates the osteogenic differentiation of rat ectomesenchymal stem cells (EMSCs) and whether SOST and low-affinity nerve growth factor receptor (LNGFR) regulate the osteogenic differentiation of EMSCs. Conclusions: SOST alleviated the osteogenic differentiation of EMSCs, and LNGFR enhanced the osteogenic differentiation of EMSCs by decreasing SOST, suggesting that the LNGFR/SOST pathway may be a novel target for promoting dental tissue regeneration and engineering.
| INTRODUCTION
Ectomesenchymal stem cells (EMSCs), which originate from the cranial neural crest (CNC), are considered to be the progenitors of almost all tooth tissues, except for enamel and maxillofacial mineralized tissues. 1 After migrating to the maxillary and mandibular processes at an early stage of embryogenesis, CNC cells are defined as EMSCs. 2 Then, the EMSCs settle down and interact with dental epithelium, ultimately differentiating into multiple dental tissue-derived cells. EMSCs serve as the primary source of differentiation, which occurs during dentin, cementum and alveolar bone formation in tooth development. 1 Therefore, there is an urgent need to investigate the mechanisms of EMSC differentiation, as they may provide potential strategies for dental tissue regeneration and engineering.
Sclerostin (SOST), which is produced by osteocytes, was originally considered to be non-classical. 3, 4 Previous studies have revealed that SOST has anti-anabolic effects on bone formation. 5 Recently, it has been reported that SOST is closely associated with the development of dental tissues. [6] [7] [8] [9] For example, SOST inhibition dramatically stimulates alveolar bone regeneration following experimental periodontitis in Sprague-Dawley (SD) rats. 6 Another report has demonstrated that SOST inhibition resulted in significant new deposition of cellular cementum and the formation of well-organized periodontal ligament fibre in a rat periodontal defect model. 7 However, it remains unknown whether SOST plays a role in the development of EMSCs, which are the progenitors of almost all tooth tissues.
Low-affinity nerve growth factor receptor (LNGFR) is a member
of the tumour necrosis factor receptor superfamily and is a receptor for neurotrophins, a family of protein growth factors that stimulate the survival and differentiation of neuronal cells. 10, 11 Previous reports have shown that LNGFR is involved in cell death and axonal degeneration in response to injury. 12 Increasing numbers of studies have demonstrated that LNGFR can serve as a cell surface marker for mesenchymal stem cells (MSCs) and that LNGFR-positive MSCs present increased potential for osteogenesis. [13] [14] [15] [16] [17] [18] SOST, which suggests that the LNGFR/SOST pathway may be a novel target for promoting dental tissue engineering and regeneration. 
| MATERIALS AND METHODS

| EMSC isolation and LNGFR
| Identification of LNGFR + and LNGFR − EMSCs
Flow cytometry analysis was used to detect the cell surface markers (CD29, CD44, CD90, CD146, CD34 and CD45) on LNGFR + and LNGFR − EMSCs. Briefly, the cells were fixed with 4% paraformaldehyde for 30 min, followed by incubation with anti-rat CD29, anti-rat CD44, anti-rat CD90, anti-rat CD146, anti-rat CD34 and anti-rat CD45 antibodies (1:100; Santa Cruz Biotechnology, Dallas, TX, USA) at 4°C overnight.
After incubation with the anti-mouse IgG-FITC secondary antibody
(1:100), the cells were analysed with a FACScalibur flow cytometer.
| Quantitative real-time PCR
Total RNA was extracted with the Trizol reagent (Invitrogen, Carlsbad, CA, USA) and first-strand cDNA was synthesized using 1 μg total RNA in 20 μL 1×PrimeScript™ RT master mix (Takara, Dalian, China). The concentrations of RNA and cDNA were measured by the ultraviolet spectrophotometer NanoDrop Lite (Thermo Scientific, Waltham, MA, USA). Quantitative real-time PCR (qPCR) was performed using 25 ng (0.5 μL) cDNA/well with the SYBRII qPCR master mix (Takara) according to the manufacturer's instruction using GAPDH as a control. The primer sets are listed in Table S1 .
| Western blot analysis
Total proteins were extracted with RIPA (Beyotime, Shanghai, China) and the protein concentrations were examined by BCA Protein Assay 
| Osteogenic induction of EMSCs
After being seeded in 6-well plates for 12 h, P3 LNGFR + and LNGFR − EMSCs (5 × 10 4 cells/well) were cultured with osteogenic induction medium, which contains 10% FBS α-MEM containing 50 mg/mL ascorbic acid, 10 mmol/L b-glycerol phosphate and 100 nM dexamethasone. The osteogenic induction medium was changed every 3 days.
| Alkaline phosphatase staining
After being seeded in 6-well plates for 12 h, P3 LNGFR + and LNGFR − EMSCs (5 × 10 4 cells/well) were cultured in osteogenic induction medium. At days 0 and 7, the cells were washed twice with PBS, fixed in 4% paraformaldehyde for 30 min and stained with an ALP activity kit (Beyotime). After washing 3 times with distilled water, the cells were observed via phase-contrast microscopy.
| Alizarin red staining
After being seeded in 6-well plates for 12 h, P3 LNGFR + and LNGFR − EMSCs (5 × 10 4 cells/well) were cultured in osteogenic induction medium. At day 21, the cells were washed twice with PBS, fixed in 4% paraformaldehyde for 30 min and stained with Alizarin red (Sangon, Shanghai, China). After washing 3 times with distilled water, the cells were visualized via phase-contrast microscopy.
| Transfection assays
After being seeded into 6-well plates for 12 h, the cells (5 × 10 4 cells/ well) were transfected with siRNAs or expression plasmids (2 μg/ well) using Lipofectamine 2000 (Invitrogen) for 24 h. Then, the cells were cultured with or without osteogenic induction medium for 7 or 21 days, followed by the corresponding experiments. The transfection assays were performed every 3 days similar to the osteogenic induction medium replacement. The sequences of the siRNAs are listed in Table S2 .
| Construction of LNGFR − EMSCs stably overexpressing LNGFR
The pLJM1-LNGFR plasmid was co-transfected with the psPAX2
envelope and CMV VSV-G packaging plasmids into HEK-293T cells using Lipofectamine 2000 for 48 h. Then, the virus-containing supernatants were collected and filtered to remove the cells. Subsequently, P3 LNGFR − EMSCs were infected in the presence of 8 μg/mL polybrene for 24 h, followed by selection with 2 μg/mL puromycin an additional 1 week.
| Statistical analysis
All data were expressed as the mean ± SD. Comparisons between 2 groups were determined with the 2-tailed unpaired t test.
Comparisons among 3 or more groups were made using one-way analysis of variance (ANOVA). P < .05 was considered to be statistically significant.
| RESULTS
| LNGFR + and LNGFR − EMSC characteristics
EMSCs were isolated from embryonic facial processes from an E12.5d pregnant SD rat. Next, the EMSCs were screened using LNGFR as a cell surface marker to obtain LNGFR + and LNGFR (E, F) The (E) qPCR and (F) Western blot analysis of LNGFR mRNA and protein levels, respectively, in LNGFR + and LNGFR − EMSCs using GAPDH as a control.
***P < .001
and LNGFR − EMSCs both showed a long spindle morphology, which is morphologically characteristic of MSCs. Moreover, MSC markers (CD29, CD44, CD90 and CD146) were highly expressed in both LNGFR + and LNGFR − EMSCs ( Figure 1C ), while hematopoietic markers (CD45 and CD34) were lowly expressed in both LNGFR + and LNGFR − EMSCs ( Figure 1D ). The mesenchymal stem markers (CD29, CD44, CD90 and CD146) were also detected in rat hematopoietic stem cells, which were used as a negative control, though they displayed expression ( Figure S1A ).
Moreover, LNGFR mRNA ( Figure 1E) 
| SOST negatively regulates the osteogenic differentiation of EMSCs
It has been reported that SOST has negative effects on bone formation; thus, we explored whether the difference in the osteogenic On day 0 and day 7, the (F, G) mRNA and (H) protein levels of ALP and RunX2 were detected by qPCR and Western blot, respectively, using GAPDH as a control. siSOST, siRNA for SOST; siNC, negative control siRNA; pMYC-SOST, SOST expression plasmid; and pMYC-NC, control plasmid; *P < .05, **P < .01, and ***P < .001
| LNGFR is present upstream of SOST and decreases SOST expression in EMSCs
The above results showed that the levels of LNGFR and SOST were negatively correlated in LNGFR + and LNGFR − EMSCs; thus, we explored whether a regulatory relationship exists between LNGFR and SOST. The mRNA ( Figure 4A ) and protein ( Figures 4B and S4A) levels of LNGFR were not regulated by SOST silencing in LNGFR − EMSCs or SOST overexpression in LNGFR + EMSCs. However, the mRNA ( Figure 4C ) and protein ( Figures 4D and S4B 
| LNGFR enhances the osteogenic differentiation of EMSCs by decreasing SOST
Because LNGFR decreased SOST expression in EMSCs and SOST in- Taken together, we demonstrated that SOST attenuates the osteogenic differentiation of EMSCs and that LNGFR strengthens the osteogenic differentiation of EMSCs. Moreover, LNGFR was present upstream of SOST and strengthens the osteogenic differentiation of EMSCs by decreasing SOST, suggesting that the LNGFR/SOST pathway may be a novel target for dental tissue engineering and regeneration.
| DISCUSSION
As a neurotrophin receptor, LNGFR has been reported to be associated with the osteogenic differentiation in several types of cells. be considered an early surface marker of in vitro osteogenic capacity. 19 Another study has shown that LNGFR overexpression promotes the proliferation and osteogenic differentiation of the MC3T3-E1
pre-osteoblast cell line through the tyrosine kinase pathway. 20 Recent evidence has demonstrated that LNGFR overexpression induces ALP activity and increases the mRNA levels of osteoblast-related genes, resulting in the enhancement of osteoblast differentiation in the human MG63 osteoblast cell line. 21 In this study, we found that LNGFR + EMSCs had higher osteogenic capacity compared with LNGFR − EMSCs. Moreover, LNGFR can promote the osteogenic differentiation of EMSCs; this was attenuated by SOST overexpression, suggesting that the LNGFR/SOST pathway may be a potent target for advancing dental tissue engineering.
SOST is a secreted glycoprotein that is synthesized and secreted by a series of steps. 22 The synthesis involves the transcription of deoxyribonucleic acid (DNA) to messenger ribonucleic acid (mRNA) in the nucleus and the conversion of the mRNA base sequence into the amino acid sequence in the protein or polypeptide chain in the ribosome. 23 After processing in the endoplasmic reticulum (ER), the protein is enclosed in vesicles, bulged by the ER and then transferred to the Golgi apparatus (GA) for further processing. 24 Subsequently, small vesicles enclosing the protein form on the edge of the GA, transport the protein to the cell membrane, fuse with the cell membrane and release the protein outside of the cell, thereby completing the protein secretion. 25 Recent studies have shown that SOST is regulated at the transcriptional level. [26] [27] [28] [29] [30] Two reports have revealed that Mef2 transcription factors bind a distal enhancer (ECR5) in the SOST locus, leading to increased SOST expression. 26, 27 Another study has reported that TGF-β also regulates SOST expression via the ECR5 enhancer. 28 Moreover,
Cohen-Kfir et al have demonstrated that Sirt1 negatively regulates
SOST expression by deacetylating histone 3 at lysine 9 in the SOST promoter. 29 Yang and his colleagues have shown that Osterix activates the SOST promoter by directly binding to the GC-rich sequence.
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Aside from transcription factors, parathyroid hormone (PTH) has been reported to be a potent negative regulator of SOST. [31] [32] [33] [34] For example, PTH infusion in healthy men induced a reduction in circulating SOST and mouse osteocytes lacking the PTH receptor display increased SOST expression. 33, 34 Moreover, prostaglandin E2, oncostatin M, cardiotrophin-1 and leukaemia inhibitory factor have also been shown to be negative regulators of SOST. [35] [36] [37] In this study, we revealed that SOST mRNA and protein levels were negatively regulated by LNGFR in EMSCs, suggesting that LNGFR may regulate SOST expression at the transcriptional level. More studies are warranted regarding the molecular mechanism by which LNGFR regulates SOST expression in EMSCs.
SOST is a vital negative regulator of bone formation. It has recently been reported that SOST inhibition increases bone formation in several disorders. [38] [39] [40] [41] [42] Delgado-Calle et al have shown that SOST inhibition augmented osteoblast numbers, promoted new bone formation and decreased osteoclast number in multiple myeloma-colonized bone. 38 McDonald and his colleague have revealed that the SOST antibody prevented myeloma-induced bone loss, decreased osteolytic bone lesions and enhanced fracture resistance. 39 Another study has
shown that osteoclast-derived leukaemia inhibitory factor suppresses SOST expression to regulate bone remodelling. 40 Moreover, SOST antibodies increase osteoclast numbers and stimulate the bone formation rate in a mouse model of recessive osteogenesis imperfect (OI) and in adults with moderate OI from a randomized phase 2a trial.
41,42
In this study, we demonstrated that SOST negatively regulated osteogenesis in EMSCs, which are the progenitors of all tooth tissues, suggesting that targeting SOST may have great prospects in dental tissue regeneration and engineering.
In summary, we revealed that LNGFR + EMSCs had a higher osteogenic capacity and lower SOST levels compared with LNGFR − EMSCs and that SOST negatively regulated the osteogenic differentiation of EMSCs. We have further shown that LNGFR is present upstream of SOST and enhanced the osteogenic differentiation of EMSCs by decreasing SOST expression. Altogether, these findings illustrated that the LNGFR/SOST pathway may be a novel target for dental tissue regeneration and engineering.
